Transpara comes to RSNA

Technology leader

ScreenPoint Medical has space at RSNA to showcase their smart breast cancer AI product Transpara. Now in use in around 20 countries across the world, Transpara is considered to be a leading contender in the world of breast cancer detection by AI. Featuring an advanced algorithm “trained” on over a million trusted, anonymised images, Transpara is clinically proven to provide decision support to improve accuracy independent of the level of experience. Transpara quickly estimates the risk of mammographic cancer shown in the scan from 1 to 10 to help radiologists with their reading workload. In this way, results can be made available quicker so saving the patient unnecessary stress and raising the success level of therapy as it will be earlier in the disease pathway.

Transpara is marketed in the USA by Siemens Healthineers USA and Volpara Solutions, a wholly owned sales and marketing arm of Volpara Health Technologies.

SPECIAL TRANSPARA EVENTS AT RSNA

Full interactive Transpara demonstrations on South Hall Level 3, #4380

Special session

Artificial Intelligence Detecting Breast Cancer in a Screening Population: Accuracy, Earlier Detection on Prior Mammograms and Relation with Cancer Grade.
Sunday, Dec. 1st 11:55am to 12:05pm in Room S406A
Two world-renowned university professors, both with a passionate belief that more women could survive breast cancer if the disease could be identified at the earliest stages, met in 2000 and agreed to share their research.

Both academics believed that harnessing the power of Artificial Intelligence (AI) to complement the work of breast radiologists was the way forward.

Prof Nico Karssemeijer (left) from Nijmegen University and Prof Sir Michael Brady (top right) from the University of Oxford, formed ScreenPoint Medical BV in 2014, building a team of specialists to help develop AI technology that could ‘review’ breast scans and quickly identify those women most at risk.

Prof Karssemeijer started ScreenPoint Medical because, “I wanted my academic work to have a greater impact than just publishing scientific papers. I knew our work had the potential to ultimately help improve breast cancer survival rates.

“I recognised the huge potential of my university team to develop a really outstanding product. Using the technological advances of Deep Learning Artificial Intelligence, we have been able to leapfrog older CAD systems to produce faster and accurate results.”

Co-Founder Sir Michael Brady was known internationally for his ground-breaking work in robotic image analysis at the University of Oxford but the death of his mother in law from breast cancer, caused him to change direction;

“I wanted to understand why the medical profession wasn't able to do a better job of detecting breast cancers at an earlier stage when they were more treatable. So I decided to move away from robotics and concentrate on the analysis of breast scans.”

“In Oxford we developed a mathematical model of the passage of X-rays through female breast tissue, a fundamental step towards developing a system able to recognise potential tumours, so joining forces with Nico was a natural progression,” he said.

Transpara is a hit at EUSOBI Budapest 2019

At the recent EUSOBI meeting in Budapest, ScreenPoint Medical launched Transpara with a series of workshops, “The Transpara Experience: multi-vendor, evidence-based breast Artificial Intelligence for mammography”.

Commercially available 2D, 3D and combo mammography solutions were on display at the ScreenPoint stand during the week. The stand displays were complemented by a series of hands-on masterclass workshops where practitioners could try the product for themselves. These workshops proved very popular.

The key to the success of the launch was breakthrough research presented at the meeting by multinational and multi-centre teams from across Europe that demonstrated Transpara’s accuracy for breast cancer detection in screening is advancing rapidly. These results give healthcare professionals yet more evidence of the success of a product that can help improve outcomes and reduce workload in European screening programs.

The research demonstrated that:

- 50% of screening exams can be safely labelled as normal using Transpara
- By replacing double with single reading for these "normal" screening mammograms, specificity can be improved with no impact on sensitivity
- This could help reduce workload in European screening programs by over 30%

Also, Transpara was demonstrated to have significantly better sensitivity for invasive and high-grade cancers in a UK screening cohort. In the same study, Transpara was also shown to have good accuracy in detecting breast cancers in the prior rounds of screening, up to three years earlier.

This positive news is enhanced by interim results from Transpara version 1.6.0 which are consistent with ScreenPoint’s aim: “Helping Radiologists to identify and diagnose breast cancer as early as possible whilst minimising problems associated with mammography including over-diagnosis.”
Transpara makes a positive difference for patients at a leading private breast screening Clinic

With Transpara™ in clinical use in around 20 countries, the system is earning praise and endorsement from far and wide.

For example, in Turkey, Professor Levent Çelik, Principal of Radiologica, a leading private breast screening clinic in Istanbul, says he is delighted with the performance of Transpara, installed in September 2018.

Professor Çelik’s clinic sees over 5,000 women annually for both screening and diagnostic mammography with the Fuji Amulet™. They are currently using Transpara light integration with tablet interface complemented by Radiologica’s customised PACS solution.

“The tablet interface is excellent and it helps with our workflow. The Exam Score from one to ten, ten meaning the scan shows a patient with a higher mammographic risk, is a superb back-up to my own decisions,” he said. “I always pay more attention to cases with a high Exam Score and at the same time, I am confident that exams with low Exam Score are highly likely to be normal.”

Transpara is making a positive difference for the women who visit the clinic. “If Transpara marks something that is visible, I can check it immediately with ultrasound to be more certain about the need for biopsy. This can help to reduce unnecessary biopsies and anxiety for many women.”

“We believe that using Transpara, we are detecting some cancers earlier. This means women can begin treatment earlier, that this treatment is potentially less invasive and it has a better outcome.”

Using Transpara in daily practice, Professor Çelik comments, “As a decision support tool, Transpara increases confidence and saves time enabling our patients to learn the results of their scans faster than before.”

Affidea

ASTERDAM, July 11, 2019 /PRNewswire/ — Affidea and ScreenPoint Medical announced a strategic partnership to streamline and improve the clinical performance of screening mammography and drive the earlier detection of breast cancer. The partnership will leverage Affidea’s growing footprint in the European breast imaging marketplace and will provide a unique opportunity for ScreenPoint Medical to implement Transpara in another three European countries - Greece, Hungary and Spain.

Giuseppe Recchi, Affidea’s CEO, stated: “This is our second AI innovative project that we embed across our European Network with the goal of expanding precision medicine, improving accuracy and driving a faster, more personalised breast care diagnosis with the help of advanced AI solutions. In this way, our doctors can take full advantage of the AI tools allowing them to foster diagnosis confidence and ultimately, save more lives. We look forward to implementing this AI for the benefit of women across Europe and to working with our partners to develop the very best clinical solutions for patients and doctors.”

Prof. Nico Karssemeijer, CEO of ScreenPoint Medical, added: “We are very excited about this strategic partnership, in which ScreenPoint will have a unique opportunity to work with the largest provider of advanced diagnostic imaging in Europe on implementation of AI in breast imaging practice. With Affidea we share the vision that innovative AI solutions are needed to help radiologists deal with increasing demands on quality and efficiency, while diagnostic imaging procedures are getting more complex. We are proud that Transpara is among the first AI applications to be implemented by Affidea and look forward to the collaboration.”
Volpara signs with ScreenPoint for USA plus

WELLINGTON, New Zealand, July 23, 2019 /PRNewswire/ -- Volpara Solutions and ScreenPoint Medical BV today announced signature of an agreement under which Volpara will sell ScreenPoint's Transpara™ products to breast imaging clinics in the United States, Australia, New Zealand, and parts of Asia. Transpara is designed to assist radiologists with the reading of mammograms and is one of the first next-generation artificial intelligence (AI) applications for detecting breast cancer in screening mammograms to gain 510(k) clearance from the US Food & Drug Administration (FDA).

FDA clearance was supported by the results of a multi-reader, multi-case reader study published in February 2019 by Rodríguez-Ruiz, et. al, in Radiology, which demonstrated that radiologists using Transpara significantly improved detection accuracy without increasing reading times. Transpara gained European regulatory approval (CE) for use with multi-vendor mammography (2018) and digital breast tomosynthesis (DBT) images (2019) and is already installed at leading breast imaging centres in Europe.

Mark Koeniguer, Volpara Chief Commercial Officer, said: "We see Transpara as a perfect complement to our industry-leading Volpara®Enterprise™ and Volpara@Live!™ image-quality-management products. More can be seen in images by Transpara when images are of good quality."

"Based on the published research to date, we strongly believe that Transpara will deliver both improved mammographic cancer detection and enhanced workflow," said Dr. Ralph Highnam, Volpara CEO. "We are delighted to have ScreenPoint join our common cause and bring this powerful software to our customers."

Prof. Nico Karssemeijer, PhD, ScreenPoint Medical CEO, said: "I am excited that ScreenPoint and Volpara will now partner to bring Transpara to the United States and other markets, as Volpara is well established in the breast space globally. Together, the two companies will help breast care teams detect cancer earlier, streamline mammography reading, and personalise screening for women."

About Volpara Solutions

Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand. Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaEnterprise is a suite of quantitative breast imaging tools for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning, and other factors designed to provide critical insight for breast imaging workflow. VolparaLive! provides technologists with real-time decision support at the point of care to assess image quality. For more information, visit www.volparasolutions.com.

Who’s Who in ScreenPoint

ScreenPoint CEO, Professor Nico Karssemeijer is a leading scientist in breast cancer imaging. A pioneer of CAD, he played a key role in its development and adoption in breast cancer screening, and was instrumental in implementing digital mammography in European screening programs. He is a Professor in the Department of Radiology, Radboud University, Nijmegen.

Chairman Professor Sir Michael Brady FRS FMedSci FReNg is a leading scientist in computer vision, robotics and medical image analysis. He co-authored Mammographic Image Analysis (Kluwer 1999) with Ralph Highnam, which led to Volpara density. Sir Michael has co-founded several successful technology companies and was until recently the Deputy Chairman of Oxford Instruments plc.

Non Executive Director Dr. Carl Everts has extensive experience founding and growing innovative medical imaging companies. He led the commercialisation of multi-modality breast reading solutions and was CEO of MeVis Medical Solutions AG and of MeVis BreastCare. He is MD and owner of Pandushi and serves on the supervisory board of Medis Medical Imaging Systems B.V.

Non Executive Director Guido du Pree M.Sc. has long experience in digital innovation and revenue growth in Medical Imaging, IVD, Healthcare Informatics and Genomics. He co-founded and managed Philips Digital Pathology venture, a leader in Philips Health growth ambitions. Recently, Guido founded an online market place for Molecular/Genetic Diagnostic tests.

Non Executive Director Anirudha Dambal has expertise in general management, strategy, product and innovation. As VP of New X-Ray Markets at Siemens Healthineers, he is responsible for identifying and developing new business opportunities in X-ray products. Before, he headed global value segment X-ray products, CRM and sales analytics and was business manager for South Asia.

Chief Operating Officer Pieter Kroese has extensive international experience, leading organisations of up to 400 people, and has developed hands-on entrepreneurial experience as co-founder of a technical startup company. He is responsible for all business activities, driving the commercial focus and growth of the company, as well as operations and finance.

Head of R&D Dr. Albert Gubern-Mérida obtained his Ph.D. in medical imaging at the Diagnostic Image Analysis Group (DIAG) of the Radboud University Medical Centre and at the University of Girona. From MRI, he expanded his research interest to other breast imaging modalities including mammography. In ScreenPoint Medical he guides the continuing evolution of our AI technology.

For more information about the people at ScreenPoint Medical, please visit our website.

Toernooiveld 300, 6525 EC Nijmegen, The Netherlands
info@screenpointmed.com www.screenpointmed.com

© ScreenPoint Medical BV